Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using 64Cu-bevacizumab ImmunoPET
Figure 4
Pre and post-treatment microPET/CT Study.
(A) Biodistribution of 64Cu-NOTA-bevacizumab in mice (n = 4 mice per group) bearing 786-O renal cell carcinoma tumors after treatment with RAD001 or vehicle. (B) Mice bearing 786-O renal cell carcinoma ear tumors were scanned at baseline following i.v. injection of 100 µCi 64Cu-NOTA-bevacizumab (n = 4). RAD001 was then administered for 7 days and the scans repeated. There was a marked decreased in 64Cu-NOTA-bevacizumab signal in the RAD001 compared to the vehicle control treated mouse. (C) Diminution of standard uptake value (SUV) in the RAD001 compared to vehicle treated mice.